Modifiable factors associated with nonadherence to maintenance medication for inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 19, Issue 10, 2013, Pages 2199-2206

  Selinger, Christian P ^a,b,f   Eaden, Jayne ^c   Brian Jones, D ^a   Katelaris, Peter ^a   Chapman, Grace ^a   McDonald, Charles ^a   Smith, Paul ^d   Lal, Simon ^b   Leong, Rupert W ^a,e   McLaughlin, John ^b   Robinson, Andrew ^b  

^a BANKSTOWN LIDCOMBE HOSPITAL   (Australia)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^d ROYAL ALBERT EDWARD INFIRMARY   (United Kingdom)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f HOPE HOSPITAL   (United Kingdom)

Author keywords

Adherence; Aminosalycilates in IBD; Biologic therapies; Compliance issues in IBD; Immunomodulators; Psychosocial aspects of IBD

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ADALIMUMAB; INFLIXIMAB; MESALAZINE;

ADULT; ANXIETY; ARTICLE; BELIEFS ABOUT MEDICINE QUESTIONNAIRE; CONTROLLED STUDY; CROHN DISEASE; DEPRESSION; ENTERITIS; FEMALE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MEDICINE ADHERENCE REPORT SCALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUESTIONNAIRE; RISK FACTOR; SHORT INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE; ULCERATIVE COLITIS;

ANXIETY DISORDERS; BIOLOGICAL FACTORS; COHORT STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; DEPRESSIVE DISORDER; DISEASE MANAGEMENT; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MEDICATION ADHERENCE; MESALAMINE; MIDDLE AGED; PROGNOSIS; QUALITY OF LIFE; RISK FACTORS;

EID: 84884585037     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e31829ed8a6     Document Type: Article

References (29)

1. Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011;60:571-607.
2. Travis SP, Stange EF, Lémann M, et al. European evidence-based consensus on the management of ulcerative colitis: current management. J Crohns Colitis. 2008;2:24-62.
3. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis. 2010;4:28-62.
4. Jackson CA, Clatworthy J, Robinson A, et al. Factors associated with nonadherence to oral medication for inflammatory bowel disease: a systematic review. Am J Gastroenterol. 2010;105:525-539.
5. Kane S, Huo D, Aikens J, et al. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003;114: 39-43.
6. Kane S, Shaya F. Medication non-adherence is associated with increased medical health care costs. Dig Dis Sci. 2008;53:1020-1024.
7. Trindade AJ, Morisky DE, Ehrlich AC, et al. Current practice and perception of screening for medication adherence in inflammatory bowel disease. J Clin Gastroenterol. 2011;45:878-882.
8. Selinger CP, Robinson A, Leong RW. Clinical impact and drivers of nonadherence to maintenance medication for inflammatory bowel disease. Expert Opin Drug Saf. 2011;10:863-870.
9. Hawthorne AB, Rubin G, Ghosh S. Review article: medication non-adherence in ulcerative colitis-strategies to improve adherence with mesalazine and other maintenance therapies. Aliment Pharmacol Ther. 2008;27: 1157-1166.
10. Waters BM, Jensen L, Fedorak RN. Effects of formal education for patients with inflammatory bowel disease: a randomized controlled trial. Can J Gastroenterol. 2005;19:235-244.
11. Moss AC, Chaudhary N, Tukey M, et al. Impact of a patient-support program on mesalamine adherence in patients with ulcerative colitis-a prospective study. J Crohns Colitis. 2010;4:171-175.
12. Moshkovska T, Stone MA, Smith RM, et al. Impact of a tailored patient preference intervention in adherence to 5-aminosalicylic acid medication in ulcerative colitis: results from an exploratory randomized controlled trial. Inflamm Bowel Dis. 2011;17:1874-1881.
13. Horne R, Parham R, Driscoll R, et al. Patients' attitudes to medicines and adherence to maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:837-844.
14. Kane SV, Robinson A. Review article: understanding adherence to medication in ulcerative colitis-innovative thinking and evolving concepts. Aliment Pharmacol Ther. 2010;32:1051-1058.
15. Stange EF, Travis SP, Vermeire S, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut. 2006;55(suppl 1):i1-i15.
16. Stange EF, Travis SP, Vermeire S, et al. European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohns Colitis. 2008;2:1-23.
17. Eaden JA, Abrams K, Mayberry JF. The Crohn's and colitis knowledge score: a test for measuring patient knowledge in inflammatory bowel disease. Am J Gastroenterol. 1999;94:3560-3566.
18. Irvine EJ, Zhou Q, Thompson AK. The short inflammatory bowel disease questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial. Am J Gastroenterol. 1996;91:1571-1578.
19. Snaith RP. The hospital anxiety and depression scale. Health Qual Life Outcomes. 2003;1:29.
20. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361-370.
21. Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health. 1999;14:1-24.
22. Horne R, Weinman J. Self-regulation and self-management in asthma: exploring the role of illness perceptions and treatment beliefs in explaining non-adherence to preventer medication. Psychol Health. 2002;17: 17-32.
23. Ediger JP, Walker JR, Graff L, et al. Predictors of medication adherence in inflammatory bowel disease. Am J Gastroenterol. 2007;102:1417-1426.
24. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet. 1998;352:98-101.
25. Kane S, Becker B, Harmsen WS, et al. Use of a screening tool to determine nonadherent behavior in inflammatory bowel disease. Am J Gastroenterol. 2012;107:154-160.
26. Lakatos PL. Prevalence, predictors, and clinical consequences of medical adherence in IBD: how to improve it? World J Gastroenterol. 2009;15: 4234-4239.
27. Taylor KM, Irving PM. Optimization of conventional therapy in patients with IBD. Nat Rev Gastroenterol Hepatol. 2011;8:646-656.
28. D'Incà R, Bertomoro P, Mazzocco K, et al. Risk factors for non-adherence to medication in inflammatory bowel disease patients. Aliment Pharmacol Ther. 2008;27:166-172.
29. Connell W, Andrews JM, Brown S, et al. Practical guidelines for treating inflammatory bowel disease safely with anti-tumour necrosis factor therapy in Australia. Intern Med J. 2010;40:139-149.